Investigating biomarkers of Staphylococcus aureus bacteremia in patients - School of Pharmacy

The Centers for Disease Control identifies methicillin-resistant S. aureus (MRSA) as a serious health threat with greater than 100,000 invasive infections and 20,000 patient deaths annually in the United States. Despite recent advancements in available treatment options for methicillin-sensitive S.

Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study - The Lancet Infectious Diseases

Full article: Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents

Frontiers Practice Summary of Antimicrobial Therapy for Commonly Encountered Conditions in the Neonatal Intensive Care Unit: A Canadian Perspective

Antibiotics, Free Full-Text

Estimation of Activity of CD14 Biomarker in Iraqi Burn Patients

Methicillin-resistant Staphylococcus aureus: novel treatment approach breakthroughs, Bulletin of the National Research Centre

Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial

Management of Staphylococcus aureus Infections

Bloodstream infections in critically ill patients: an expert statement

AFMR Southeastern Regional Meeting Supplement, 2023

Frontiers Clinical Characteristics of Bloodstream Infection in Immunosuppressed Patients: A 5-Year Retrospective Cohort Study

Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice, Journal of Nanobiotechnology

ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment - Philip Kam-Tao Li, Kai Ming Chow, Yeoungjee Cho, Stanley Fan, Ana E Figueiredo, Tess Harris, Talerngsak Kanjanabuch, Yong-Lim Kim, Magdalena Madero